ライフサイエンスコーパス: tenofovir disoproxil

1 creatinine increases than those given E/C/F/tenofovir disoproxil fumarate (0.08 vs 0.12 mg/dL; p<0.0

2 21 were in those assigned emtricitabine plus tenofovir disoproxil fumarate (0.48 cases per 100 person

3 73, 95% confidence interval [CI] 0.56-0.96), tenofovir disoproxil fumarate (0.68, 95% CI 0.49-0.95),

4 Any plaque was negatively associated with tenofovir disoproxil fumarate (0.71, 95% CI 0.51-0.99).

5 r (400/100 mg) twice daily and emtricitabine/tenofovir disoproxil fumarate (200/300 mg) once daily.

6 mly assigned (1:1) to receive daily combined tenofovir disoproxil fumarate (245 mg) and emtricitabine

7 rticipants were given combination tablets of tenofovir disoproxil fumarate (300 mg) and emtricitabine

8 ee-drug regimen of dolutegravir (50 mg) plus tenofovir disoproxil fumarate (300 mg) and emtricitabine

9 namide group), or emtricitabine (200 mg) and tenofovir disoproxil fumarate (300 mg) tablets daily, wi

10 virenz (600 mg), emtricitabine (200 mg), and tenofovir disoproxil fumarate (300 mg), with matching pl

11 ivirine (25 mg), emtricitabine (200 mg), and tenofovir disoproxil fumarate (300 mg), with matching pl

12 10 mg) daily or continued therapy containing tenofovir disoproxil fumarate (300 mg).

13 similar to that seen with oral emtricitabine/tenofovir disoproxil fumarate (94.0%; 55.1%-99.2%).

14 ted with each additional year of exposure to tenofovir disoproxil fumarate (adjusted incidence rate r

15 elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (combined ART).

16 8 versus 130 (93%) of 140 patients receiving tenofovir disoproxil fumarate (difference 1.8% [95% CI -

17 Nine participants switched from E/C/F/tenofovir disoproxil fumarate (E/C/F/TDF 150/150/200/300

18 mide (E/C/F/tenofovir alafenamide) or 300 mg tenofovir disoproxil fumarate (E/C/F/tenofovir disoproxi

19 TC/TDF) with that of efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF).

20 acy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/c/FTC/TDF) with that

21 fumarate (TDF) and combination emtricitabine/tenofovir disoproxil fumarate (FTC+TDF), is efficacious

22 ated that combination oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) as preexposure p

23 ophylaxis (PrEP) with oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) decreases the ri

24 Background therapies were emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in P007; abacavi

25 e prophylaxis (PrEP) with emtricitabine plus tenofovir disoproxil fumarate (FTC/TDF) or TDF alone red

26 f daily oral co-formulated emtricitabine and tenofovir disoproxil fumarate (FTC/TDF).

27 in bone mineral density than those receiving tenofovir disoproxil fumarate (hip -0.29% [95% CI -0.55

28 ections, 31 occurred in individuals assigned tenofovir disoproxil fumarate (incidence 0.71 cases per

29 elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (integrase inhibitor regim

30 o 100 mg, 67 to 200 mg, and 66 to 400 mg) or tenofovir disoproxil fumarate (n=101).

31 ir alafenamide (n=2694) or emtricitabine and tenofovir disoproxil fumarate (n=2693).

32 eive either tenofovir alafenamide (n=333) or tenofovir disoproxil fumarate (n=330).

33 , and tenofovir alafenamide (n=111 [66%]) or tenofovir disoproxil fumarate (n=56 [34%]).

34 among participants receiving efavirenz with tenofovir disoproxil fumarate (p=0.001) but not those re

35 ir-boosted atazanavir with emtricitabine and tenofovir disoproxil fumarate (protease inhibitor based

36 After adjustment, persons who had ever used tenofovir disoproxil fumarate (TDF) (1.40; 1.15-1.70) or

37 enofovir prodrugs - TAF (TAF-based group) or tenofovir disoproxil fumarate (TDF) (TDF-based group) -

38 a 3-arm randomized, pharmacokinetic study of tenofovir disoproxil fumarate (TDF) 300 mg/emtricitabine

39 prophylaxis (PrEP) using the antiretroviral tenofovir disoproxil fumarate (TDF) alone or in combinat

40 oviral preexposure prophylaxis (PrEP), using tenofovir disoproxil fumarate (TDF) and combination emtr

41 y randomized to the efavirenz /emtricitabine/tenofovir disoproxil fumarate (TDF) and dolutegravir/emt

42 e randomly assigned to take a combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (F

43 Oral tenofovir disoproxil fumarate (TDF) and emtricitabine (F

44 the NAPs REP 2139 or REP 2165 combined with tenofovir disoproxil fumarate (TDF) and pegylated interf

45 ed drug combinations have been marketed, and tenofovir disoproxil fumarate (TDF) and tenofovir alafen

46 In the present study, we show that tenofovir disoproxil fumarate (TDF) and tenofovir alafen

47 emtricitabine (FTC), rilpivirine (RPV), and tenofovir disoproxil fumarate (TDF) as a 3-drug, single-

48 viral therapy currently receive some form of tenofovir disoproxil fumarate (TDF) as part of their HIV

49 ose DOR at 100 mg, lamivudine at 300 mg, and tenofovir disoproxil fumarate (TDF) at 300 mg (DOR/3TC/T

50 The approved tenofovir disoproxil fumarate (TDF) dose of 300 mg every

51 Tenofovir disoproxil fumarate (TDF) has been linked to r

52 itis B e antigen positive patients receiving tenofovir disoproxil fumarate (TDF) in an open-label, lo

53 Despite widespread use of tenofovir disoproxil fumarate (TDF) in pregnant and brea

54 The efficacy and safety of maternal tenofovir disoproxil fumarate (TDF) in reducing mother-t

55 Tenofovir disoproxil fumarate (TDF) is active against la

56 Tenofovir disoproxil fumarate (TDF) is an established nu

57 Tenofovir disoproxil fumarate (TDF) is associated with p

58 Tenofovir disoproxil fumarate (TDF) is commonly used in

59 Tenofovir disoproxil fumarate (TDF) is one of the nucleo

60 Exposure to tenofovir disoproxil fumarate (TDF) may cause renal toxi

61 Tenofovir disoproxil fumarate (TDF) plays a pivotal role

62 Clinical studies of systemic tenofovir disoproxil fumarate (TDF) PrEP revealed reduce

63 emtricitabine (FTC) resistance and increased tenofovir disoproxil fumarate (TDF) susceptibility.

64 change in participants switching from E/C/F/tenofovir disoproxil fumarate (TDF) to E/C/F/TAF.

65 from patients with rapid or slow response to tenofovir disoproxil fumarate (TDF) treatment, have been

66 d, double-blind, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks ge

67 Although tenofovir disoproxil fumarate (TDF) use has increased as

68 ravir, cobicistat, emtricitabine (E/C/F) and tenofovir disoproxil fumarate (TDF) who switched to E/C/

69 Replacing tenofovir disoproxil fumarate (TDF) with tenofovir alafe

70 differ among patients receiving LDV/SOF and tenofovir disoproxil fumarate (TDF) without a protease i

71 2a for 96 weeks and combination therapy with tenofovir disoproxil fumarate (TDF) would increase hepat

72 Once-daily oral tenofovir disoproxil fumarate (TDF), alone or combined w

73 lone, MVC plus emtricitabine (FTC), MVC plus tenofovir disoproxil fumarate (TDF), and TDF plus FTC.

74 MVC only, MVC-emtricitabine (FTC), MVC-tenofovir disoproxil fumarate (TDF), and TDF-FTC (contro

75 nd 7 had M184V/I (0.1%), despite high use of tenofovir disoproxil fumarate (TDF), emtricitabine, and

76 ug of tenofovir and a potential successor of tenofovir disoproxil fumarate (TDF), has been approved i

77 ed trial to assess daily treatment with oral tenofovir disoproxil fumarate (TDF), oral tenofovir-emtr

78 l to demonstrate that a novel gel containing tenofovir disoproxil fumarate (TDF), the more potent pro

79 ophylaxis (PrEP) with a novel gel containing tenofovir disoproxil fumarate (TDF), the tenofovir prodr

80 It is unknown if tenofovir disoproxil fumarate (TDF), which is often cofo

81 We compared maraviroc (MVC)- to tenofovir disoproxil fumarate (TDF)-containing ART.

82 importance of renal and endocrine changes in tenofovir disoproxil fumarate (TDF)-related bone toxicit

83 cluding the clinically approved formulation, tenofovir disoproxil fumarate (TDF).

84 ylactic efficacy of oral emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF).

85 ion in persons living with HIV (PLWH) taking tenofovir disoproxil fumarate (TDF).

86 s and hospital admission by use of the NRTIs tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC),

87 PLWH receiving tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)/

88 men with symptomatic HSV-2 infection to oral tenofovir disoproxil fumarate (TDF)/placebo vaginal gel,

89 andomly assigned to groups given either oral tenofovir disoproxil fumarate (TDF, 300 mg) and placebo

90 Tenofovir disoproxil fumarate (tenofovir) has been assoc

91 elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (tenofovir) might be a saf

92 ed protease inhibitor and emtricitabine plus tenofovir disoproxil fumarate (tenofovir) regimen to cof

93 fenamide 0.01 mg/dL [95% CI 0.00 to 0.02] vs tenofovir disoproxil fumarate 0.02 mg/dL [0.00 to 0.04],

94 (tenofovir alafenamide 40 [14%] patients vs tenofovir disoproxil fumarate 14 [10%] patients), nasoph

95 0 mg; once-daily oral fixed-dose combination tenofovir disoproxil fumarate 300 mg and emtricitabine 2

96 , 200 mg, or 400 mg once a day or to receive tenofovir disoproxil fumarate 300 mg once a day; each al

97 oral doses of tenofovir alafenamide 25 mg or tenofovir disoproxil fumarate 300 mg, each with matching

98 ) ritonavir (RTV) or standard of care (SOC) (tenofovir disoproxil fumarate 300 mg, emtricitabine 200

99 or once-daily oral fixed-dose combination of tenofovir disoproxil fumarate 300 mg, emtricitabine 200

100 AD from the DOR groups (DOR/lamivudine [3TC]/tenofovir disoproxil fumarate [TDF] or DOR [100 mg daily

101 was not significantly different from that of tenofovir disoproxil fumarate alone (hazard ratio [HR] 0

102 ety and efficacy of daily oral emtricitabine-tenofovir disoproxil fumarate among HIV-seronegative men

103 ciated with noncalcified/mixed plaque, while tenofovir disoproxil fumarate and efavirenz were negativ

104 Daily, oral use of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC

105 ry of Food and Drug Safety in Korea approved tenofovir disoproxil fumarate and emtricitabine (TDF/FTC

106 Preexposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine (Truvada

107 disoproxil fumarate monotherapy or combined tenofovir disoproxil fumarate and emtricitabine and whet

108 effect in a context that also includes oral tenofovir disoproxil fumarate and emtricitabine as an op

109 eness of the new product in addition to oral tenofovir disoproxil fumarate and emtricitabine as compa

110 As pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine for the

111 f pre-exposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine in 2499

112 tonavir-boosted atazanavir plus coformulated tenofovir disoproxil fumarate and emtricitabine once a d

113 th darunavir/ritonavir and 2 nucleos(t)ides (tenofovir disoproxil fumarate and emtricitabine or abaca

114 g (one tablet) orally twice daily, each with tenofovir disoproxil fumarate and emtricitabine orally o

115 lled three-group phase 3 trial of daily oral tenofovir disoproxil fumarate and emtricitabine plus ten

116 acquisition, the protective efficacy of oral tenofovir disoproxil fumarate and emtricitabine relies o

117 ent film colour), and lamivudine tablets and tenofovir disoproxil fumarate and emtricitabine tablets

118 atinine clearance and the number of doses of tenofovir disoproxil fumarate and emtricitabine taken pe

119 Pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine was adop

120 ing that they are non-inferior to daily oral tenofovir disoproxil fumarate and emtricitabine.

121 Patients started RAL in combination with tenofovir disoproxil fumarate and lamivudine after initi

122 iated with less renal and bone toxicity than tenofovir disoproxil fumarate and might improve the long

123 In contrast, tenofovir disoproxil fumarate and tenofovir alafenamide

124 In contrast, tenofovir disoproxil fumarate and tenofovir alafenamide

125 We quantified tenofovir disoproxil fumarate and tenofovir concentratio

126 BMS-986001 had similar efficacy to that of tenofovir disoproxil fumarate and was associated with a

127 ir disoproxil fumarate or emtricitabine plus tenofovir disoproxil fumarate and were followed up for H

128 e relative to combination emtricitabine plus tenofovir disoproxil fumarate as PrEP.

129 ir disoproxil fumarate or emtricitabine plus tenofovir disoproxil fumarate as PrEP.

130 bolite to target cells more efficiently than tenofovir disoproxil fumarate at a lower dose, thereby r

131 -six CHB patients who started treatment with tenofovir disoproxil fumarate at a public hospital in Et

132 /ADAPT) of oral PrEP with emtricitabine plus tenofovir disoproxil fumarate at a research centre in Ca

133 Tenofovir disoproxil fumarate can cause renal and bone t

134 elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate compared with a boosted pr

135 a slight difference in HIV-1 protection with tenofovir disoproxil fumarate compared with emtricitabin

136 d trial of PrEP with oral emtricitabine plus tenofovir disoproxil fumarate compared with placebo in m

137 disoproxil fumarate; one patient assigned to tenofovir disoproxil fumarate did not receive the treatm

138 r alafenamide and 12 (4%) patients receiving tenofovir disoproxil fumarate experienced serious advers

139 d eGFR included traditional risk factors and tenofovir disoproxil fumarate exposure.

140 men and had been on daily emtricitabine and tenofovir disoproxil fumarate for 8 months presented wit

141 ies per mL) on efavirenz, emtricitabine, and tenofovir disoproxil fumarate for at least 6 months befo

142 s per mL) on rilpivirine, emtricitabine, and tenofovir disoproxil fumarate for at least 6 months befo

143 inferior efficacy to daily emtricitabine and tenofovir disoproxil fumarate for HIV prevention, and th

144 namide was non-inferior to emtricitabine and tenofovir disoproxil fumarate for HIV prevention, as the

145 nofovir alafenamide versus emtricitabine and tenofovir disoproxil fumarate for HIV prevention.

146 p<0.0001) and 93% for the emtricitabine plus tenofovir disoproxil fumarate group (0.07, 0.02-0.23; p<

147 and 15 participants in the emtricitabine and tenofovir disoproxil fumarate group (0.34 infections per

148 amide group and in 444 (93%) assigned to the tenofovir disoproxil fumarate group (adjusted difference

149 r alafenamide group and -0.10% (3.39) in the tenofovir disoproxil fumarate group (between-group diffe

150 enamide group compared with 307 (93%) in the tenofovir disoproxil fumarate group (difference 1.3%, 95

151 r alafenamide group and -0.73% (3.21) in the tenofovir disoproxil fumarate group (difference 2.04% [1

152 risk reduction in HIV-1 acquisition for the tenofovir disoproxil fumarate group (HR 0.15, 95% CI 0.0

153 per mL, compared with 88 (89%) of 99 in the tenofovir disoproxil fumarate group (modified intention-

154 lated to study treatment; one patient in the tenofovir disoproxil fumarate group died, but this was n

155 fovir alafenamide (2%) and three (1%) in the tenofovir disoproxil fumarate group discontinued due to

156 namide group and one (2%) participant in the tenofovir disoproxil fumarate group had an adverse event

157 de group and 96 (33%) of 292 patients in the tenofovir disoproxil fumarate group had grade 3 or 4 lab

158 ruption and thrombocytopenia) and two in the tenofovir disoproxil fumarate group had study drug-relat

159 e group and 784 (90%) of 867 patients in the tenofovir disoproxil fumarate group having plasma HIV-1

160 vir disoproxil fumarate-containing regimens (tenofovir disoproxil fumarate group) for 96 weeks.

161 e tenofovir alafenamide group and 314 to the tenofovir disoproxil fumarate group).

162 f 2693 participants in the emtricitabine and tenofovir disoproxil fumarate group).

163 h matched placebo tablets (emtricitabine and tenofovir disoproxil fumarate group).

164 fovir alafenamide group; and one (2%) in the tenofovir disoproxil fumarate group).

165 of 437 in the efavirenz, emtricitabine, and tenofovir disoproxil fumarate group.

166 e tenofovir alafenamide group and 477 to the tenofovir disoproxil fumarate group.

167 alafenamide group compared with those in the tenofovir disoproxil fumarate group.

168 our [7%]), and arthralgia (four [7%]) in the tenofovir disoproxil fumarate group.

169 e group compared with 37 (12%) of 314 in the tenofovir disoproxil fumarate group; none of these were

170 enofovir alafenamide and 294 (94%) of 313 on tenofovir disoproxil fumarate had maintained less than 5

171 alafenamide and nine (6%) patients receiving tenofovir disoproxil fumarate had serious adverse events

172 s given E/C/F/tenofovir alafenamide or E/C/F/tenofovir disoproxil fumarate had virological success.

173 Antiretroviral regimens containing tenofovir disoproxil fumarate have been associated with

174 lafenamide was superior to emtricitabine and tenofovir disoproxil fumarate in all six prespecified bo

175 pen-label study of rilpivirine/emtricitabine/tenofovir disoproxil fumarate in ART-naive HIV controlle

176 daily oral tenofovir disoproxil fumarate or tenofovir disoproxil fumarate in combination with emtric

177 or to continuing rilpivirine, emtricitabine, tenofovir disoproxil fumarate in maintaining viral suppr

178 the efficacy and safety of BMS-986001 versus tenofovir disoproxil fumarate in treatment-naive patient

179 ily use of PrEP with oral emtricitabine plus tenofovir disoproxil fumarate in women.

180 ty, pharmacokinetics, and acceptability of a tenofovir disoproxil fumarate intravaginal ring used con

181 Emtricitabine with tenofovir disoproxil fumarate is a standard-of-care nucl

182 However, tenofovir disoproxil fumarate is associated with renal a

183 re prophylaxis (PrEP) with emtricitabine and tenofovir disoproxil fumarate is highly effective agains

184 Daily emtricitabine/tenofovir disoproxil fumarate is recommended as preexpos

185 ophylaxis (PrEP) with oral emtricitabine and tenofovir disoproxil fumarate is used to prevent the sex

186 or the prevention of HIV infection with oral tenofovir disoproxil fumarate monotherapy or combined te

187 reased risk of HIV infection, PrEP with oral tenofovir disoproxil fumarate monotherapy or tenofovir d

188 mg of raltegravir twice daily and 300 mg of tenofovir disoproxil fumarate once daily as a backbone.

189 transcriptase inhibitors: emtricitabine and tenofovir disoproxil fumarate or abacavir and lamivudine

190 SVR12 among patients receiving either tenofovir disoproxil fumarate or abacavir as part of the

191 should be followed; adjustment should avoid tenofovir disoproxil fumarate or boosted protease inhibi

192 re offered rerandomisation in a 1:1 ratio to tenofovir disoproxil fumarate or emtricitabine plus teno

193 4410 (99.6%) of 4427 couples received tenofovir disoproxil fumarate or emtricitabine plus teno

194 oxil fumarate, but show that once-daily oral tenofovir disoproxil fumarate or emtricitabine plus teno

195 ravir combined with emtricitabine and either tenofovir disoproxil fumarate or tenofovir alafenamide),

196 exposure prophylaxis (PrEP), with daily oral tenofovir disoproxil fumarate or tenofovir disoproxil fu

197 Second, the effectiveness of tenofovir disoproxil fumarate plus emtricitabine varies

198 hylaxis (PrEP), using daily oral combination tenofovir disoproxil fumarate plus emtricitabine, is an

199 l tissue exposure by the third daily dose of tenofovir disoproxil fumarate plus emtricitabine.

200 given a new PrEP agent or oral coformulated tenofovir disoproxil fumarate plus emtricitabine.

201 open-label study of daily oral emtricitabine-tenofovir disoproxil fumarate PrEP among 50 HIV-uninfect

202 r disoproxil fumarate and emtricitabine plus tenofovir disoproxil fumarate PrEP in HIV-1 uninfected i

203 regimen and 402 (92%) of 437 assigned to the tenofovir disoproxil fumarate regimen (difference -2.0%,

204 eived one dose of study drug and were on the tenofovir disoproxil fumarate regimen before screening w

205 ir disoproxil fumarate or emtricitabine plus tenofovir disoproxil fumarate regimens both provide high

206 We assessed the efficacy of single-agent tenofovir disoproxil fumarate relative to combination em

207 12 were assigned to receive the tenofovir disoproxil fumarate ring and five were assigne

208 days 14 and 28 compared with baseline in the tenofovir disoproxil fumarate ring group but not the pla

209 Two participants in the tenofovir disoproxil fumarate ring group completed 3 mon

210 grade 2 adverse events were reported in the tenofovir disoproxil fumarate ring group.

211 d finding of ulcerations is specific to this tenofovir disoproxil fumarate ring or generalisable to o

212 V negative were randomly assigned (3:1) to a tenofovir disoproxil fumarate ring or placebo ring.

213 ility of switching from a regimen containing tenofovir disoproxil fumarate to elvitegravir, cobicista

214 n patients switching from emtricitabine with tenofovir disoproxil fumarate to emtricitabine with teno

215 nsity of switching from a regimen containing tenofovir disoproxil fumarate to one containing tenofovi

216 responses were independent of emtricitabine/tenofovir disoproxil fumarate use.

217 d tenofovir alafenamide to emtricitabine and tenofovir disoproxil fumarate was established if the upp

218 amide-containing regimen from one containing tenofovir disoproxil fumarate was non-inferior for maint

219 afenamide from efavirenz, emtricitabine, and tenofovir disoproxil fumarate was non-inferior in mainta

220 prevention efficacy with emtricitabine plus tenofovir disoproxil fumarate was not significantly diff

221 previous use of PrEP with emtricitabine and tenofovir disoproxil fumarate were not excluded.

222 improved renal and bone safety compared with tenofovir disoproxil fumarate when used for HIV treatmen

223 erior to the 195 (67%) of patients receiving tenofovir disoproxil fumarate who had HBV DNA less than

224 either 25 mg tenofovir alafenamide or 300 mg tenofovir disoproxil fumarate with matching placebo.

225 amide and 36 [13%] of 288 patients receiving tenofovir disoproxil fumarate) and AST (20 [3%] of 577 p

226 n (efavirenz combined with emtricitabine and tenofovir disoproxil fumarate) previously recommended by

227 ndividuals on cART (predominantly containing tenofovir disoproxil fumarate) were also more likely to

228 300 mg tenofovir disoproxil fumarate (E/C/F/tenofovir disoproxil fumarate) with matching placebo.

229 enamide vs 22 [8%] of 292 patients receiving tenofovir disoproxil fumarate), nasopharyngitis (56 [10%

230 amide and 437 with efavirenz, emtricitabine, tenofovir disoproxil fumarate).

231 men (both regimens include emtricitabine and tenofovir disoproxil fumarate).

232 (581 with tenofovir alafenamide and 292 with tenofovir disoproxil fumarate).

233 namide and 19 [7%] of 288 patients receiving tenofovir disoproxil fumarate).

234 /F/tenofovir alafenamide and 867 given E/C/F/tenofovir disoproxil fumarate).

235 lus combination emtricitabine, 200 mg/d, and tenofovir disoproxil fumarate, 300 mg/d.

236 de was associated with more weight gain than tenofovir disoproxil fumarate, abacavir, or zidovudine.

237 ses of CAB LA, 6 received oral emtricitabine/tenofovir disoproxil fumarate, and 10 were untreated.

238 retroviral therapy (ART; combined efavirenz, tenofovir disoproxil fumarate, and emtricitabine).

239 ovir alafenamide was non-inferior to that of tenofovir disoproxil fumarate, and had improved bone and

240 n, tenofovir alafenamide was non-inferior to tenofovir disoproxil fumarate, and had improved bone and

241 l density than a standard regimen containing tenofovir disoproxil fumarate, and might be a treatment

242 il fumarate compared with emtricitabine plus tenofovir disoproxil fumarate, but show that once-daily

243 group, 275 (78%) of 351 participants in the tenofovir disoproxil fumarate, emtricitabine, and dolute

244 and dolutegravir group; 4.3 kg [6.7] in the tenofovir disoproxil fumarate, emtricitabine, and dolute

245 citabine, and dolutegravir group, 351 to the tenofovir disoproxil fumarate, emtricitabine, and dolute

246 wer among infants exposed from conception to tenofovir disoproxil fumarate, emtricitabine, and efavir

247 up, and 258 (74%) of 351 participants in the tenofovir disoproxil fumarate, emtricitabine, and efavir

248 dolutegravir group, and 2.3 kg [7.0] in the tenofovir disoproxil fumarate, emtricitabine, and efavir

249 bine, and dolutegravir group, and 351 to the tenofovir disoproxil fumarate, emtricitabine, and efavir

250 Ten (3%) of 351 participants in the tenofovir disoproxil fumarate, emtricitabine, and efavir

251 Compared with tenofovir disoproxil fumarate, individuals in the BMS-98

252 the antiretrovirals abacavir sulphate (ABC), tenofovir disoproxil fumarate, or tenofovir alafenamide.

253 al ring that releases the tenofovir prodrug, tenofovir disoproxil fumarate, provided 100% protection

254 of 99 and one (1%) of 99 patients receiving tenofovir disoproxil fumarate, respectively.

255 azanavir/ritonavir, lopinavir/ritonavir, and tenofovir disoproxil fumarate, respectively.

256 e increased for up to 6 years of exposure to tenofovir disoproxil fumarate, ritonavir-boosted atazana

257 sease associated with cumulative exposure to tenofovir disoproxil fumarate, ritonavir-boosted atazana

258 r plasma concentrations by 90% compared with tenofovir disoproxil fumarate, thereby decreasing bone a

259 cells more efficiently at a lower dose than tenofovir disoproxil fumarate, thereby reducing systemic

260 e 200 mg emtricitabine with 200 mg or 300 mg tenofovir disoproxil fumarate, while remaining on the sa

261 ofovir alafenamide was non-inferior to E/C/F/tenofovir disoproxil fumarate, with 800 (92%) of 866 pat

262 tenofovir alafenamide was as efficacious as tenofovir disoproxil fumarate, with reduced bone and ren

263 cells and EMP had greater TF activity, while tenofovir disoproxil fumarate- and tenofovir alafenamide

264 lso extend to HIV-negative individuals using tenofovir disoproxil fumarate-based pre-exposure prophyl

265 t the magnitude of benefit of PrEP with oral tenofovir disoproxil fumarate-based therapy to reduce th

266 Nearly all (97.6%) patients received tenofovir disoproxil fumarate-containing ART, in line wi

267 copies per mL), aged 60 years or older, on a tenofovir disoproxil fumarate-containing regimen and wer

268 ) or to carry on taking one of four previous tenofovir disoproxil fumarate-containing regimens (tenof

269 min or greater, and were taking one of four tenofovir disoproxil fumarate-containing regimens for at

270 improved renal and bone safety compared with tenofovir disoproxil fumarate-containing regimens.

271 oninferior and potentially safer option than tenofovir disoproxil fumarate-emtricitabine (F/TDF) for

272 aive participants were randomized to receive tenofovir disoproxil fumarate-emtricitabine (TDF/FTC) pl

273 lights the importance of expanding access to tenofovir disoproxil fumarate-sparing regimens in resour

274 come region of enrollment, hypertension, and tenofovir disoproxil fumarate.

275 osted protease inhibitor, emtricitabine, and tenofovir disoproxil fumarate.

276 n coformulated efavirenz, emtricitabine, and tenofovir disoproxil fumarate.

277 despite consistent use of emtricitabine and tenofovir disoproxil fumarate.

278 non-inferiority of tenofovir alafenamide to tenofovir disoproxil fumarate.

279 remaining on rilpivirine, emtricitabine, and tenofovir disoproxil fumarate.

280 ir-boosted atazanavir with emtricitabine and tenofovir disoproxil fumarate.

281 versus in those remaining on one containing tenofovir disoproxil fumarate.

282 argin of tenofovir alafenamide compared with tenofovir disoproxil fumarate.

283 improved renal and bone safety compared with tenofovir disoproxil fumarate.

284 in patients switched from emtricitabine with tenofovir disoproxil fumarate.

285 n with initiation of efavirenz/emtricitabine/tenofovir disoproxil fumarate.

286 inavir/ritonavir, or efavirenz/emtricitabine/tenofovir disoproxil fumarate.

287 rkers of renal safety than emtricitabine and tenofovir disoproxil fumarate.

288 rom pivotal studies using oral emtricitabine-tenofovir disoproxil fumarate.

289 This study estimated the number of daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) do

290 phylaxis (PrEP) interventions worldwide, yet tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) fo

291 ment-naive individuals randomized equally to tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) pl

292 P utilization as the number of people taking tenofovir disoproxil fumarate/emtricitabine for HIV prev

293 Daily tenofovir disoproxil fumarate/emtricitabine is recommend

294 ed ART-naive participants were randomized to tenofovir disoproxil fumarate/emtricitabine plus atazana

295 s who lost bone mineral density (BMD) during tenofovir disoproxil fumarate/emtricitabine preexposure

296 tenofovir disoproxil fumarate monotherapy or tenofovir disoproxil fumarate/emtricitabine was associat

297 se inhibitors (NRTIs; abacavir/lamivudine or tenofovir disoproxil fumarate/emtricitabine) and a third

298 HIV in Kampala, Uganda, and receiving daily tenofovir disoproxil fumarate/lamivudine were recruited.

299 to tenofovir alafenamide and 141 assigned to tenofovir disoproxil fumarate; one patient assigned to t

300 articipants were randomized 1:1:1 to receive tenofovir-disoproxil fumarate (DF) plus emtricitabine, a

301 e-exposure prophylaxis (PrEP) in the form of tenofovir-disoproxil-fumarate/emtricitabine is being imp

302 ng fixed-dose combination emtricitabine with tenofovir disoproxil fumartate from 78 sites in North Am

303 enrollment, participants received daily oral tenofovir disoproxil fumurate and emtricitabine for HIV